Cargando…

Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo

Neuraminidase (NA) is a pivotal surface enzyme and a key therapeutic target in combating the influenza A virus. Its evolution can lead to potential zoonotic transmission, seasonal epidemics, and the emergence of drug-resistant mutants. To gain comprehensive insights into the mutational effects and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sihan, Zhang, Tian-hao, Hu, Menglong, Tang, Kejun, Sheng, Li, Hong, Mengying, Chen, Dongdong, Chen, Liubo, Shi, Yuan, Feng, Jun, Qian, Jing, Sun, Lifeng, Ding, Kefeng, Sun, Ren, Du, Yushen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654105/
https://www.ncbi.nlm.nih.gov/pubmed/37772870
http://dx.doi.org/10.1128/msystems.00670-23
_version_ 1785136559245230080
author Wang, Sihan
Zhang, Tian-hao
Hu, Menglong
Tang, Kejun
Sheng, Li
Hong, Mengying
Chen, Dongdong
Chen, Liubo
Shi, Yuan
Feng, Jun
Qian, Jing
Sun, Lifeng
Ding, Kefeng
Sun, Ren
Du, Yushen
author_facet Wang, Sihan
Zhang, Tian-hao
Hu, Menglong
Tang, Kejun
Sheng, Li
Hong, Mengying
Chen, Dongdong
Chen, Liubo
Shi, Yuan
Feng, Jun
Qian, Jing
Sun, Lifeng
Ding, Kefeng
Sun, Ren
Du, Yushen
author_sort Wang, Sihan
collection PubMed
description Neuraminidase (NA) is a pivotal surface enzyme and a key therapeutic target in combating the influenza A virus. Its evolution can lead to potential zoonotic transmission, seasonal epidemics, and the emergence of drug-resistant mutants. To gain comprehensive insights into the mutational effects and drug resistance profiles of NA, we employed a high-throughput profiling system to quantify the replication capacity of NA mutants at the single-nucleotide level in mouse lung tissues. The fitness of NA mutants is generally correlated with natural mutation occurrence and is constrained by both the requirement to maintain protein stability and NA function. Leveraging this system, we profiled the drug resistance to the three most commonly used neuraminidase inhibitors (NAIs): zanamivir, oseltamivir, and peramivir. In addition to identifying previously reported drug resistance mutations, we validated novel mutants. Notably, we identified an allosteric mutation that confers resistance to all three drugs, which may affect drug binding by interfering with the tetramerization of NA. Moreover, the fitness cost associated with drug-resistant mutations may limit their widespread dissemination. In summary, we provided a parallel characterization of NA’s fitness and drug resistance landscape in an in vivo context, which may guide the rational selection of antiviral drugs for optimal therapeutic efficacy and second-generation NAI development. IMPORTANCE: NA is a crucial surface antigen and drug target of influenza A virus. A comprehensive understanding of NA’s mutational effect and drug resistance profiles in vivo is essential for comprehending the evolutionary constraints and making informed choices regarding drug selection to combat resistance in clinical settings. In the current study, we established an efficient deep mutational screening system in mouse lung tissues and systematically evaluated the fitness effect and drug resistance to three neuraminidase inhibitors of NA single-nucleotide mutations. The fitness of NA mutants is generally correlated with a natural mutation in the database. The fitness of NA mutants is influenced by biophysical factors such as protein stability, complex formation, and the immune response triggered by viral infection. In addition to confirming previously reported drug-resistant mutations, novel mutations were identified. Interestingly, we identified an allosteric drug-resistance mutation that is not located within the drug-binding pocket but potentially affects drug binding by interfering with NA tetramerization. The dual assessments performed in this study provide a more accurate assessment of the evolutionary potential of drug-resistant mutations and offer guidance for the rational selection of antiviral drugs.
format Online
Article
Text
id pubmed-10654105
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-106541052023-09-29 Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo Wang, Sihan Zhang, Tian-hao Hu, Menglong Tang, Kejun Sheng, Li Hong, Mengying Chen, Dongdong Chen, Liubo Shi, Yuan Feng, Jun Qian, Jing Sun, Lifeng Ding, Kefeng Sun, Ren Du, Yushen mSystems Research Article Neuraminidase (NA) is a pivotal surface enzyme and a key therapeutic target in combating the influenza A virus. Its evolution can lead to potential zoonotic transmission, seasonal epidemics, and the emergence of drug-resistant mutants. To gain comprehensive insights into the mutational effects and drug resistance profiles of NA, we employed a high-throughput profiling system to quantify the replication capacity of NA mutants at the single-nucleotide level in mouse lung tissues. The fitness of NA mutants is generally correlated with natural mutation occurrence and is constrained by both the requirement to maintain protein stability and NA function. Leveraging this system, we profiled the drug resistance to the three most commonly used neuraminidase inhibitors (NAIs): zanamivir, oseltamivir, and peramivir. In addition to identifying previously reported drug resistance mutations, we validated novel mutants. Notably, we identified an allosteric mutation that confers resistance to all three drugs, which may affect drug binding by interfering with the tetramerization of NA. Moreover, the fitness cost associated with drug-resistant mutations may limit their widespread dissemination. In summary, we provided a parallel characterization of NA’s fitness and drug resistance landscape in an in vivo context, which may guide the rational selection of antiviral drugs for optimal therapeutic efficacy and second-generation NAI development. IMPORTANCE: NA is a crucial surface antigen and drug target of influenza A virus. A comprehensive understanding of NA’s mutational effect and drug resistance profiles in vivo is essential for comprehending the evolutionary constraints and making informed choices regarding drug selection to combat resistance in clinical settings. In the current study, we established an efficient deep mutational screening system in mouse lung tissues and systematically evaluated the fitness effect and drug resistance to three neuraminidase inhibitors of NA single-nucleotide mutations. The fitness of NA mutants is generally correlated with a natural mutation in the database. The fitness of NA mutants is influenced by biophysical factors such as protein stability, complex formation, and the immune response triggered by viral infection. In addition to confirming previously reported drug-resistant mutations, novel mutations were identified. Interestingly, we identified an allosteric drug-resistance mutation that is not located within the drug-binding pocket but potentially affects drug binding by interfering with NA tetramerization. The dual assessments performed in this study provide a more accurate assessment of the evolutionary potential of drug-resistant mutations and offer guidance for the rational selection of antiviral drugs. American Society for Microbiology 2023-09-29 /pmc/articles/PMC10654105/ /pubmed/37772870 http://dx.doi.org/10.1128/msystems.00670-23 Text en Copyright © 2023 Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Wang, Sihan
Zhang, Tian-hao
Hu, Menglong
Tang, Kejun
Sheng, Li
Hong, Mengying
Chen, Dongdong
Chen, Liubo
Shi, Yuan
Feng, Jun
Qian, Jing
Sun, Lifeng
Ding, Kefeng
Sun, Ren
Du, Yushen
Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo
title Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo
title_full Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo
title_fullStr Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo
title_full_unstemmed Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo
title_short Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo
title_sort deep mutational scanning of influenza a virus neuraminidase facilitates the identification of drug resistance mutations in vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654105/
https://www.ncbi.nlm.nih.gov/pubmed/37772870
http://dx.doi.org/10.1128/msystems.00670-23
work_keys_str_mv AT wangsihan deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT zhangtianhao deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT humenglong deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT tangkejun deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT shengli deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT hongmengying deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT chendongdong deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT chenliubo deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT shiyuan deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT fengjun deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT qianjing deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT sunlifeng deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT dingkefeng deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT sunren deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo
AT duyushen deepmutationalscanningofinfluenzaavirusneuraminidasefacilitatestheidentificationofdrugresistancemutationsinvivo